Home » Gilead Sciences Annual Reports » 2012 Annual Report - page 8

Gilead Sciences 2012 Annual Report Download - page 8

Download and view the complete annual report

Please find page 8 of the 2012 Gilead Sciences annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

1
2
3
4
5
6
7
8
9
10
11
12
13

Roberto Tascione, General Manager, Italy, Gilead Sciences

EU MARKETING APPROVAL SUBMITTED

STRIBILD® (ELVITEGRAVIR 150MG/COBICISTAT 150MG/

EMTRICITABINE 200MG/TENOFOVIR DISOPROXIL

FUMARATE 300MG)

POTENTIAL INDICATION: HIV/AIDS

U.S. AND EU MARKETING APPROVALS SUBMITTED

COBICISTAT (PHARMACOKINETIC ENHANCER)

POTENTIAL INDICATION: HIV/AIDS

ELVITEGRAVIR (INTEGRASE INHIBITOR)

POTENTIAL INDICATION: HIV/AIDS

PHASE 3

SINGLE TABLET REGIMEN OF ELVITEGRAVIR/COBICISTAT/

EMTRICITABINE/TENOFOVIR ALAFENAMIDE

POTENTIAL INDICATION: HIV/AIDS

PHASE 2

SINGLE TABLET REGIMEN OF DARUNAVIR/COBICISTAT/

EMTRICITABINE/TENOFOVIR ALAFENAMIDE

POTENTIAL INDICATION: HIV/AIDS

Gilead is working to develop the next generation of HIV

single tablet regimens that are effective, tolerable and

convenient and that may provide certain advantages

over existing treatment options. This is particularly

important as more individuals with HIV are diagnosed

and brought into care, because life-long treatment is

required to control the virus.

We are conducting clinical trials of tenofovir alafen-

amide (TAF; GS-7340); TAF may be able to exhibit greater

antiviral efﬁcacy than Viread® at a dose that is 10 times

lower, which may improve the tolerability of HIV therapy.

Phase 3 studies will examine a once-daily single tablet

regimen of TAF, Emtriva,

® the integrase inhibitor

elvitegravir and the boosting agent cobicistat, compared

to Stribild® among patients new to HIV therapy.

While HIV medicines reduce the level of virus in the

blood to undetectable levels, the ultimate goal is to

develop a cure. Gilead scientists are engaged in early-

stage research to identify novel therapeutic agents that

may help eradicate HIV infection.

FOCUS AREA

HIV/AIDS

FINANCIAL

HIGHLIGHTS

* The earnings per share calculations for all

periods presented reflect the two-for-one stock

split effective on January 25, 2013.

• Non-GAAP diluted earnings per share for 2010

exclude the impact of after-tax acquisition-

related expenses of $0.08, restructuring

expenses of $0.02 and stock-based

compensation expenses of $0.08.

• Non-GAAP diluted earnings per share for 2011

exclude after-tax acquisition-related expenses

of $0.05 and stock-based compensation

expenses of $0.09.

• Non-GAAP diluted earnings per share for 2012

exclude after-tax acquisition-related expenses

of $0.08, restructuring expenses of $0.01 and

stock-based compensation expenses of $0.22.

EARNINGS PER SHARE

10 11 12

GAAP DILUTED

EARNINGS PER SHARE

NON-GAAP DILUTED

EARNINGS PER SHARE

*

$

2.00 –

$

1.75–

$

1.50–

$

1.25 –

$

1.00 –

$

.75 –

$

.50 –

$

.25 –

$

0 –

PRODUCT SALES

($ IN MILLIONS)

10 11 12

$1

0,000 –

$ 9,000 –

$ 8,000 –

$ 7, 000 –

$ 6,000 –

$ 5,000 –

$ 4,000 –

$ 3,000 –

$ 2,000 –

$ 1,000 –

$ 0 –

OTHER

AMBISOME

RANEXA

LETAIRIS

ANTIVIRAL

FRANCHISE

TOTAL REVENUES

($ IN MILLIONS)

10 11 12

$1

0,000 –

$ 9,000 –

$ 8,000 –

$ 7, 000 –

$ 6,000 –

$ 5,000 –

$ 4,000 –

$ 3,000 –

$ 2,000 –

$ 1,000 –

$ 0 –

OPERATING CASH FLOW

($ IN MILLIONS)

$

4,000 –

$

3,500 –

$

3,000 –

$

2,500 –

$

2,000 –

$

1,500 –

$

1,000 –

$

500 –

$

0 –

10 11 12

1312